Olema Oncology, Inc. (OLMA)
NASDAQ · Manufacturing · Pharmaceutical preparations
OLMA price, last 12 months
Key stats
- Previous close
- $7.06
- Open
- $7.07
- Day range
- $6.77 – $7.41
- 52-week range
- $6.24 – $36.26
- Volume
- 1.8M
- Avg volume (20 days)
- 1.5M
- Market cap
- $662.3M
Performance
Technicals and fundamentals
About Olema Oncology, Inc.
Olema Oncology Inc is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The company's lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), is currently in two Phase 3 clinical trials. In addition, Olema is focused in developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $662.3M